Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 10/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30307535 | 1.00 | TSHR (0.44) | TSHRPDE4BPTGDR2CNR2 | |
| SCHEMBL8707829 | 0.81 | PDE4B (0.43) | PDE4B | |
| SCHEMBL5274226 | 0.77 | TSHR (0.41) | TSHRPDE4BPTGDR2CNR2 | |
| SCHEMBL6783812 | 0.76 | TSHR (0.39) | TSHRPDE4BPTGDR2CNR2 | |
| SCHEMBL7175438 | 0.75 | PTGDR2 (0.39) | TSHRPDE4BPTGDR2 | |
| SCHEMBL22946143 | 0.75 | TSHR (0.41) | TSHRPDE4BPTGDR2CNR2 | |
| SCHEMBL5330768 | 0.75 | MRGPRX4 (0.43) | TSHRPTGDR2 | |
| SCHEMBL6788039 | 0.75 | TSHR (0.38) | TSHRPDE4BPTGDR2CNR2 | |
| SCHEMBL1714808 | 0.75 | TSHR (0.39) | TSHRPDE4BPTGDR2CNR2 | |
| SCHEMBL26662458 | 0.75 | PPARA (0.51) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286960-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11649227-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2023-05-16 | — | — | US | disclosed |
| CN-115956075-A | Allosteric enone inhibitors of phosphoinositide 3-kinases (PI 3 ks) for the treatment of diseases associated with PI3K modulation | 佩特拉制药公司 | 2023-04-11 | — | — | CN | disclosed |
| US-20220372023-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2022-11-24 | — | — | US | disclosed |
| US-20040092754-A1 | Derivatives of 4-(trifluoromethyl)-phenol and 4-(trifluoromethylphenyl)-2-(tetrahydropyranyl) ether and method for producing the same | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-13 | — | — | US | disclosed |
| EP-1309531-A1 | DERIVATIVES OF 4-(TRIFLUOROMETHYL)-PHENOL AND 4-(TRIFLUOROMETHYLPHENYL)-2-(TETRAHYDROPYRANYL) ETHER AND METHOD FOR PRODUCING THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002014250-A1 | DERIVATIVES OF 4-(TRIFLUOROMETHYL)-PHENOL AND 4-(TRIFLUOROMETHYLPHENYL)-2-(TETRAHYDROPYRANYL) ETHER AND METHOD FOR PRODUCING THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286960-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, AKT3, PIK3R1 | TSHR 505/4885PDE4B 957/4885PTGDR2 2954/4885 |
| US-20040092754-A1 | Derivatives of 4-(trifluoromethyl)-phenol and 4-(trifluoromethylphenyl)-2-(tetrahydropyranyl) ether and method for producing the same | EPX, CYP4X1, EPHX2 | TSHR 2704/4885PDE4B 1837/4885PTGDR2 1603/4885 |
| US-20220372023-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, AKT3, PIK3R1 | TSHR 505/4885PDE4B 957/4885PTGDR2 2954/4885 |
| US-11649227-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PIK3CA, AKT3, PIK3R1 | TSHR 505/4885PDE4B 957/4885PTGDR2 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.